HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) 081430.Supplemental Data All Versions of this Article: clinchem.2006.081430v1 53/4/757    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Ghosh, S. K. Articles by Weinberg, A. Search for Related Content PubMed PubMed Citation Articles by Ghosh, S. K. Articles by Weinberg, A. Related Collections Clinical Immunology Proteomics and Protein Markers

Quantification of Human ß-Defensin-2 and -3 in Body Fluids: Application for Studies of Innate Immunity

¹ Department of Biological Sciences, Case School of Dental Medicine;
² Departments of Pediatrics and Biochemistry, Case Western Reserve University, Cleveland, OH.
³ Department of Dermatology, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, OH.

^aAddress correspondence to this author at: School of Dental Medicine, Case Western Reserve University, Cleveland, OH 44106-4905. Fax 216-368-0145; e-mail aaron.weinberg{at}case.edu.

Background: Human ß-defensins (hBDs) are epithelial cell-derived antimicrobial and immunoregulatory cationic peptides. Our objective was to establish an analytical tool to quantify inducible hBD-2 and -3 in body fluids.

Methods: We developed sandwich ELISAs using commercially available capture and detection antibodies and determined optimal assay conditions (with 250 mmol/L CaCl₂) to overcome masking by endogenous components of body fluids. We used recombinant hBD as calibrators and for recovery testing.

Results: hBD-2 and -3 detection limits were 75 ng/L and 3 µg/L, respectively. Mean (SD range) values in saliva samples from healthy donors (n = 60) were 9.5 (1.2–21) µg/L for hBD-2 and 326 (50–931) µg/L for hBD-3. We did not detect hBD-3 in suction blister fluid (BF; n = 10) or bronchoalveolar lavage (BAL; n = 5) from healthy participants. We detected low hBD-2 peptide concentrations in BF and BAL, 0.16 (0.03–0.32) and 0.04 (0–0.049) µg/g total protein, respectively. We observed no correlation of hBD-2 in BF and saliva or BAL and saliva from the same person. In vaginal swabs from healthy women (n = 2), mean hBD-2 and -3 concentrations were 3.42 and 103 µg/g total protein, respectively. Cervicovaginal lavage from the same women contained mean concentrations of 1.46 and 55.5 µg/g total protein.

Conclusion: These ELISA assays can measure inducible hBD peptide concentrations in body fluids by overcoming masking effects of anionic molecules. This approach may therefore be applicable for quantifying these peptides in health and disease.

The following articles in journals at HighWire Press have cited this article:

				D. E. Dietrich, X. Xiao, D. V. Dawson, M. Belanger, H. Xie, A. Progulske-Fox, and K. A. Brogden Human {alpha}- and {beta}-Defensins Bind to Immobilized Adhesins from Porphyromonas gingivalis Infect. Immun., December 1, 2008; 76(12): 5714 - 5720. [Abstract] [Full Text] [PDF]